KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Inventory (2016 - 2026)

Supernus Pharmaceuticals has reported Inventory over the past 14 years, most recently at $82.4 million for Q4 2025.

  • Quarterly Inventory rose 51.74% to $82.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $82.4 million through Dec 2025, up 51.74% year-over-year, with the annual reading at $82.4 million for FY2025, 51.74% up from the prior year.
  • Inventory was $82.4 million for Q4 2025 at Supernus Pharmaceuticals, up from $79.4 million in the prior quarter.
  • Over five years, Inventory peaked at $91.5 million in Q4 2022 and troughed at $44.0 million in Q2 2025.
  • The 5-year median for Inventory is $78.4 million (2023), against an average of $73.1 million.
  • Year-over-year, Inventory surged 105.69% in 2021 and then plummeted 35.41% in 2025.
  • A 5-year view of Inventory shows it stood at $86.0 million in 2021, then increased by 6.49% to $91.5 million in 2022, then decreased by 15.44% to $77.4 million in 2023, then fell by 29.86% to $54.3 million in 2024, then soared by 51.74% to $82.4 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Inventory are $82.4 million (Q4 2025), $79.4 million (Q3 2025), and $44.0 million (Q2 2025).